Efficacy and Safety of Lanoracopan in the Treatment of PNH
NCT07788105 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90
Last updated 2026-08-26
Summary
This study aimed to evaluate the efficacy and safety of Lanoracopan Hydrochloride in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions
- DRUG
-
Lanoracopan Hydrochloride
400mg bid
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
More Related Trials
-
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06134414 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT07177859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03181633 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06050226 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07256301 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT03472885 ·Status: COMPLETED ·Phase: PHASE2
-
Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
NCT03866681 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia
NCT07052838 ·Status: COMPLETED ·Phase: PHASE3
-
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
NCT05116787 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06933914 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06578949 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
NCT06561841 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06745622 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01335165 ·Status: TERMINATED ·Phase: PHASE1
-
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
NCT07187401 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07229235 ·Status: RECRUITING
-
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT06799546 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
NCT01642979 ·Status: UNKNOWN ·Phase: PHASE2
-
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT00438789 ·Status: APPROVED_FOR_MARKETING
-
Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
NCT05125341 ·Status: COMPLETED
-
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02598583 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
NCT05116774 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
NCT04085601 ·Status: COMPLETED ·Phase: PHASE3